Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | NNMT | P40261 | 5/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17796149 | 0.86 | SIRT6 (0.39) | SIRT6NNMTSLC9A1LMNAGABRP | |
| SCHEMBL7813902 | 0.84 | GABRP (0.47) | SIRT6LMNAGABRPGABRDGABRA1 | |
| SCHEMBL20331043 | 0.84 | SIRT6 (0.47) | SIRT6NNMTLMNAMKNK1MKNK2 | |
| SCHEMBL26765951 | 0.82 | GABRP (0.38) | SIRT6NNMTLMNAGABRPGABRD | |
| SCHEMBL384113 | 0.82 | NNMT (0.61) | SIRT6NNMTLMNASLC2A1MKNK1 | |
| SCHEMBL29799541 | 0.82 | NNMT (0.61) | SIRT6NNMTLMNASLC2A1MKNK1 | |
| SCHEMBL2339686 | 0.79 | GABRP (0.50) | NNMTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30096979 | 0.78 | NNMT (0.59) | SIRT6NNMTSLC2A1GABRPGABRD | |
| SCHEMBL22291660 | 0.78 | NNMT (0.59) | SIRT6NNMTSLC2A1GABRPGABRD | |
| SCHEMBL4499056 | 0.78 | ABL1 (0.56) | LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743068-B1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS INC (US) | 2026-04-29 | — | — | EP | disclosed |
| CN-116472047-B | Arylamine derivative, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-12195475-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-112312909-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382248-B2 | Mnk inhibitors and methods related thereto | EFFECTOR THERAPEUTICS, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160168125-A1 | WNT SIGNALING INHIBITOR | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3028703-A1 | Wnt SIGNALING INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-06-08 | — | — | EP | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2015-12-31 | — | — | US | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708367-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | SIRT6 1919/4885NNMT 507/4885SLC9A1 4327/4885 |
| US-20150376181-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | SIRT6 4030/4885NNMT 663/4885SLC9A1 597/4885 |
| US-20230374024-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, ERBB3, MAP3K6 | SIRT6 1919/4885NNMT 507/4885SLC9A1 4327/4885 |
| US-12195475-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, ERBB3, MAP3K6 | SIRT6 1919/4885NNMT 507/4885SLC9A1 4327/4885 |
| US-20160168125-A1 | WNT SIGNALING INHIBITOR | WNT3A, WNT1, WNT3 | SIRT6 3863/4885NNMT 3629/4885SLC9A1 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.